Medicis Pharmaceutical Corporation

Lupin, Inc.

The Board of Regents Acting for and on Behalf of the University of

Douglas Anthony Bakan

Mitchell S Wortzman

Steven B Newhard

Waranush Jitpraphai

Jamey Paul Weichert

Raymond E Counsell

Shirishkumar Kulkarni

Tushar Sopan Jadhav

Marc A Longino

Ashish Ashokrao Deshmukh

Sajeev Chandran

Pravin Meghrajji Bhutada

Amol Subhash Mandhare

Mukesh Kumar

Nilendu Sen

Provided herein are compositions and methods for treating or preventing a skin disease or skin condition on the skin of a subject by administering a topical flunisolide composition comprising a therapeutically effective amount of flunisolide and a solubilizing agent that solubilizes the flunisolide.

Topical compositions of flunisolide and methods of treatment

The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.

Controlled release pharmaceutical dosage forms

The present disclosure relates to dosage forms and methods that enhance the absorption of minocycline in the gastrointestinal tract and thereby enhance bioavailability of the minocycline, and further provides methods of using these dosage forms for the treatment of conditions such as acne.

Gastroretentive dosage forms for minocycline

The present disclosure relates to dosage forms, e.g., swell, float and bioadhesive, and methods that enhance the absorption of doxycycline in the gastrointestinal tract. The oral dosage forms control the spatial and temporal delivery of doxycycline in the gastrointestinal tract. This controlled spatial and temporal delivery provides a site and rate of release, respectively, of the doxycycline into the gastrointestinal tract that enhances the amount of the doxycycline absorbed into the bloodstream.

Gastroretentive dosage forms for doxycycline

Hepatocyte-selective oil-in-water emulsion

Growing community of inventors

San Diego, CA, United States of America

Douglas Anthony Bakan